Fundraising FoxVeana Therapeutics
Portland, US · Founded 2015 · Delaware corporation · 2 known investors
Find your way into Veana Therapeutics
Sign up to see every warm intro you have to Veana Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Veana Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
FA
F Andrew RayNamed on SEC filing
MF
Mark F HoliferNamed on SEC filing
EA
Emmanuel AkporiayeNamed on SEC filing
RA
Rebecca AkporiayeNamed on SEC filing
AD
Andrew D ThalerNamed on SEC filing
DR
Denis R BurgerNamed on SEC filing
TE
Thomas E McChesneyNamed on SEC filing
TD
Trent D DavisNamed on SEC filing
Investors · 2
Elevate Capitallisted by Elevate CapitalPortland · $2M – $25M
How we know: Elevate Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Portfolialisted by PortfoliaSan Mateo
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$1.4M disclosed across 2 rounds · 2018–2020
▶$831KraisedNov 2020 · 4 investors · PharmaceuticalsRule 506(b)
▶$831KraisedNov 2020 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- EMMANUEL AKPORIAYEExecutive Officer, Director
- SANDRA SHOTWELLDirector
- REBECCA AKPORIAYEExecutive Officer, Director
- BRUCE RAMSEYERDirector
- ANDREW RAYDirector
- Offering amount
- $1.3M
- Amount sold
- $831K
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 04, 06b
▶$542KraisedMay 2018 · 9 investors · BiotechnologyRule 506(b)
▶$542KraisedMay 2018 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- F Andrew RayDirector
- Mark F HoliferExecutive Officer, Director, Promoter
- Emmanuel AkporiayeExecutive Officer, Director, Promoter
- Rebecca AkporiayeExecutive Officer, Director
- Andrew D ThalerExecutive Officer
- Denis R BurgerDirector
- Thomas E McChesneyExecutive Officer
- Trent D DavisDirector
- Offering amount
- $2M
- Amount sold
- $542K
- Minimum investment
- $5K
- Proceeds to insiders
- $100K
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $400K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $350.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- Who are Veana Therapeutics's investors?
- Veana Therapeutics's investors include Elevate Capital, Portfolia.
- How much funding has Veana Therapeutics raised?
- Veana Therapeutics has disclosed $1.4M raised across 2 rounds.
- Where is Veana Therapeutics headquartered?
- Veana Therapeutics is headquartered in Portland, US.